Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Current Assets (2021 - 2025)

Historic Current Assets for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $353.4 million.

  • Amylyx Pharmaceuticals' Current Assets rose 4408.33% to $353.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $353.4 million, marking a year-over-year increase of 4408.33%. This contributed to the annual value of $189.4 million for FY2024, which is 5923.27% down from last year.
  • Per Amylyx Pharmaceuticals' latest filing, its Current Assets stood at $353.4 million for Q3 2025, which was up 4408.33% from $186.9 million recorded in Q2 2025.
  • Amylyx Pharmaceuticals' 5-year Current Assets high stood at $464.7 million for Q4 2023, and its period low was $105.0 million during Q4 2021.
  • Its 5-year average for Current Assets is $299.0 million, with a median of $296.1 million in 2022.
  • Its Current Assets has fluctuated over the past 5 years, first skyrocketed by 26410.61% in 2022, then crashed by 5923.27% in 2024.
  • Quarter analysis of 5 years shows Amylyx Pharmaceuticals' Current Assets stood at $105.0 million in 2021, then soared by 264.11% to $382.1 million in 2022, then increased by 21.6% to $464.7 million in 2023, then tumbled by 59.23% to $189.4 million in 2024, then skyrocketed by 86.55% to $353.4 million in 2025.
  • Its Current Assets stands at $353.4 million for Q3 2025, versus $186.9 million for Q2 2025 and $216.1 million for Q1 2025.